Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Ul. Miklukho-Maklaya 16/10, 117997 Moscow, Russia.
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Trubetskaya Str. 8, Bld. 2, 119991 Moscow, Russia.
Int J Mol Sci. 2024 Jan 24;25(3):1413. doi: 10.3390/ijms25031413.
Tafalgin (Taf) is a tetrapeptide opioid used in clinical practice in Russia as an analgesic drug for subcutaneous administration as a solution (4 mg/mL; concentration of 9 mM). We found that the acid-sensing ion channels (ASICs) are another molecular target for this molecule. ASICs are proton-gated sodium channels that mediate nociception in the peripheral nervous system and contribute to fear and learning in the central nervous system. Using electrophysiological methods, we demonstrated that Taf could increase the integral current through heterologically expressed ASIC with half-maximal effective concentration values of 0.09 mM and 0.3 mM for rat and human ASIC3, respectively, and 1 mM for ASIC1a. The molecular mechanism of Taf action was shown to be binding to the channel in the resting state and slowing down the rate of desensitization. Taf did not compete for binding sites with both protons and ASIC3 antagonists, such as APETx2 and amiloride (Ami). Moreover, Taf and Ami together caused an unusual synergistic effect, which was manifested itself as the development of a pronounced second desensitizing component. Thus, the ability of Taf to act as a positive allosteric modulator of these channels could potentially cause promiscuous effects in clinical practice. This fact must be considered in patients' treatment.
他法辛(Tafalgin,Taf)是一种在俄罗斯临床实践中用作皮下注射用的四肽阿片类药物的镇痛药(4mg/mL;浓度为 9mM)。我们发现酸敏离子通道(ASICs)是该分子的另一个分子靶点。ASICs 是质子门控的钠离子通道,在周围神经系统中介导伤害感受,并有助于中枢神经系统中的恐惧和学习。使用电生理方法,我们证明 Taf 可以增加通过异源表达的 ASIC 的积分电流,对于大鼠和人 ASIC3 的半最大有效浓度值分别为 0.09mM 和 0.3mM,对于 ASIC1a 为 1mM。Taf 作用的分子机制被证明是与通道在静息状态下结合,并减缓脱敏的速度。Taf 与质子和 ASIC3 拮抗剂(如 APETx2 和阿米洛利(Ami))都不竞争结合位点。此外,Taf 和 Ami 一起产生了一种不寻常的协同作用,表现为明显的第二个脱敏成分的发展。因此,Taf 作为这些通道的正变构调节剂的能力可能会在临床实践中引起混杂效应。在患者治疗中必须考虑到这一事实。